A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Two patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

Analysts anticipate Altimmune to report an earnings per share (EPS) of $-0.34. The announcement from Altimmune is eagerly ...

Walnuts, brazil nuts, and almonds are rich in omega-3 fatty acids and vitamin E, both of which help reduce oxidative stress ...

From 2006 to 2019, age-adjusted mortality for liver disease in the US increased by 14% overall and by 24% during COVID, from 2019 through 2021.

Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads ...